 Hydroxyurea is an established first-line treatment option currently approved in several European countries for Polycythemia Vera PV patients requiring a cytoreductive therapy Barbui et al, 2011. Clinical trials have shown that HU is an effective drug for preventing thrombosis in PV compared to phlebotomy Michiels et al, 1999. 